Optimization and interpretation of serial QuantiFERON testing to measure acquisition of mycobacterium tuberculosis infection

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 5, 2017, Pages 638-648

  Nemes, Elisa ^a,b   Rozot, Virginie ^a,b   Geldenhuys, Hennie ^a,b   Bilek, Nicole ^a,b   Mabwe, Simbarashe ^a,b   Abrahams, Deborah ^a,b   Makhethe, Lebohang ^a,b   Erasmus, Mzwandile ^a,b   Keyser, Alana ^a,b   Toefy, Asma ^a,b   Cloete, Yolundi ^a,b   Ratangee, Frances ^a,b   Blauenfeldt, Thomas ^c   Ruhwald, Morten ^c   Walzl, Gerhard ^d   Smith, Bronwyn ^d   Loxton, Andre G ^d   Hanekom, Willem A ^a,b   Andrews, Jason R ^e   Lempicki, Maria D ^f   Ellis, Ruth ^f   Ginsberg, Ann M ^f   Hatherill, Mark ^a,b   Scriba, Thomas J ^a,b   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c STATENS SERUM INSTITUT   (Denmark)

^d UNIVERSITY OF STELLENBOSCH   (South Africa)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f AERAS   (United States)

Author keywords

Conversion; IFN g release assay; QuantiFERON; Tuberculosis; Variability

Indexed keywords

GAMMA INTERFERON;

ADOLESCENT; ALGORITHM; ARTICLE; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INCIDENCE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MYCOBACTERIUM TUBERCULOSIS TEST KIT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; STANDARD; TUBERCULIN TEST; ADULT; BLOOD; FEMALE; IMMUNOLOGY; MALE; MYCOBACTERIUM TUBERCULOSIS; PROCEDURES; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, PULMONARY;

ADOLESCENT; ADULT; FEMALE; HUMANS; INTERFERON-GAMMA; MALE; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 85029469386     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201704-0817OC     Document Type: Article

References (32)

1. Machingaidze S, Verver S, Mulenga H, Abrahams DA, Hatherill M, Hanekom W, Hussey GD, Mahomed H. Predictive value of recent QuantiFERON conversion for tuberculosis disease in adolescents. Am J Respir Crit Care Med 2012;186:1051-1056.
2. Andrews JR, Nemes E, Tameris M, Landry BS, Mahomed H, McClain JB, Fletcher HA, Hanekom WA, Wood R, McShane H, et al. Serial QuantiFERON testing and tuberculosis disease risk among young children: an observational cohort study. Lancet Respir Med 2017;5: 282-290.
3. World Health Organization (WHO). Guidelines on the management of latent tuberculosis infection. Geneva, Switzerland: WHO; 2015.
4. Pai M, Denkinger CM, Kik SV, Rangaka MX, Zwerling A, Oxlade O, Metcalfe JZ, Cattamanchi A, Dowdy DW, Dheda K, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev 2014;27:3-20.
5. Tagmouti S, Slater M, Benedetti A, Kik SV, Banaei N, Cattamanchi A, Metcalfe J, Dowdy D, van Zyl Smit R, Dendukuri N, et al. Reproducibility of interferon gamma (IFN-g) release assays: A systematic review. Ann Am Thorac Soc 2014;11:1267-1276.
6. Joshi M, Monson TP, Joshi A, Woods GL. IFN-g release assay conversions and reversions: challenges with serial testing in U.S. health care workers. Ann Am Thorac Soc 2014;11:296-302.
7. Zwerling A, Joshi R, Kalantri SP, Dakshinamoorthy G, Reddy MV, Benedetti A, Schwartzman K, Menzies D, Pai M. Trajectories of tuberculosis-specific interferon-gamma release assay responses among medical and nursing students in rural India. J Epidemiol Glob Health 2013;3:105-117.
8. Moses MW, Zwerling A, Cattamanchi A, Denkinger CM, Banaei N, Kik SV, Metcalfe J, Pai M, Dowdy D. Serial testing for latent tuberculosis using QuantiFERON-TB Gold In-Tube: A Markov model. Sci Rep 2016; 6:30781.
9. Pai M. Serial testing with TB interferon-g release assays: toward a nuanced understanding. Chest 2012;142:1366-1368.
10. Zellweger JP, Sotgiu G, Block M, Dore S, Altet N, Blunschi R, Bogyi M, Bothamley G, Bothe C, Codecasa L, et al.; TBNET. Risk assessment of tuberculosis in contacts by IFN-g release assays: A Tuberculosis Network European Trials Group study. Am J Respir Crit Care Med 2015;191:1176-1184.
11. Department of Health, Republic of South Africa. National tuberculosis management guidelines 2014. Pretoria, South Africa: Department of Health, Republic of South Africa; 2014.
12. Ellis RD, Hatherill M, Tait D, Snowden M, Churchyard G, Hanekom W, Evans T, Ginsberg AM. Innovative clinical trial designs to rationalize TB vaccine development. Tuberculosis (Edinb) 2015;95:352-357.
13. Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev 2014; 78:650-671.
14. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection -United States, 2010. MMWR Recomm Rep 2010;59:1-25.
15. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test variability of the QuantiFERON-TB Gold In-Tube assay in clinical practice. Am J Respir Crit Care Med 2013;187:206-211.
16. van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, et al. Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing. Am J Respir Crit Care Med 2009;180:49-58.
17. Pai M, Joshi R, Dogra S, Mendiratta DK, Narang P, Kalantri S, Reingold AL, Colford JM Jr, Riley LW, Menzies D. Serial testing of health care workers for tuberculosis using interferon-g assay. Am J Respir Crit Care Med 2006;174:349-355.
18. Mahomed H, Hawkridge T, Verver S, Geiter L, Hatherill M, Abrahams DA, Ehrlich R, Hanekom WA, Hussey GD; SATVI Adolescent Study Team. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int J Tuberc Lung Dis 2011;15:331-336.
19. Andrews JR, Hatherill M, Mahomed H, Hanekom WA, Campo M, Hawn TR, Wood R, Scriba TJ. The dynamics of QuantiFERON-TB Gold In-Tube conversion and reversion in a cohort of South African adolescents. Am J Respir Crit Care Med 2015;191:584-591.
20. Mahomed H, Ehrlich R, Hawkridge T, Hatherill M, Geiter L, Kafaar F, Abrahams DA, Mulenga H, Tameris M, Geldenhuys H, et al. Screening for TB in high school adolescents in a high burden setting in South Africa. Tuberculosis (Edinb) 2013;93: 357-362.
21. Mugan K, Carlson IH, Westgard JO. Planning QC procedures for immunoassays. J Clin Immunoassay 1994;17:216-222.
22. Esmail H, Thienemann F, Oni T, Goliath R, Wilkinson KA, Wilkinson RJ. QuantiFERON conversion following tuberculin administration is common in HIV infection and relates to baseline response. BMC Infect Dis 2016;16:545.
23. Penn-Nicholson A, Nemes E, Hanekom WA, Hatherill M, Scriba TJ. Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-g in QuantiFERON assays in healthy persons. Tuberculosis (Edinb) 2015;95:350-351.
24. Woo KS, Choi JL, Kim BR, Han JY, Kim JM, Kim KH. Repeatability of QuantiFERON-TB Gold In-Tube assay results near cut-off points. Ann Lab Med 2016;36:76-78.
25. Banaei N, Gaur RL, Pai M. Interferon gamma release assays for latent tuberculosis: what are the sources of variability? J Clin Microbiol 2016;54:845-850.
26. Gaur RL, Banaei N. Inoculation of QuantiFERON-TB tubes with skin microbiota causes false-positive results. Am J Respir Crit Care Med 2014;190:834-837.
27. Gaur RL, Pai M, Banaei N. Impact of blood volume, tube shaking, and incubation time on reproducibility of QuantiFERON-TB Gold In-Tube assay. J Clin Microbiol 2013;51:3521-3526.
28. Doberne D, Gaur RL, Banaei N. Preanalytical delay reduces sensitivity of QuantiFERON-TB Gold In-Tube assay for detection of latent tuberculosis infection. J Clin Microbiol 2011;49: 3061-3064.
29. Herrera V, Yeh E, Murphy K, Parsonnet J, Banaei N. Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold In-Tube assay. J Clin Microbiol 2010;48: 2672-2676.
30. Shanaube K, De Haas P, Schaap A, Moyo M, Kosloff B, Devendra A, Raby E, Godfrey-Faussett P, Ayles H. Intra-assay reliability and robustness of QuantiFERON®-TB Gold In-Tube test in Zambia. Int J Tuberc Lung Dis 2010;14:828-833.
31. Detjen AK, Loebenberg L, Grewal HMS, Stanley K, Gutschmidt A, Kruger C, Du Plessis N, Kidd M, Beyers N, Walzl G, et al. Short-term reproducibility of a commercial interferon gamma release assay. Clin Vaccine Immunol 2009;16:1170-1175.
32. Whitworth WC, Hamilton LR, Goodwin DJ, Barrera C, West KB, Racster L, Daniels LJ, Chuke SO, Campbell BH, Bohanon J, et al. Withinsubject interlaboratory variability of QuantiFERON-TB Gold In-Tube tests. PLoS One 2012;7:e43790.